Avatrombopag is named as an intervention in 4 current clinical trials in our China and USA registers. 4 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (2). The most-studied condition is Immune Thrombocytopenia.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
NCT04993885 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Autoantibodies, Evan Syndrome
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327 · ClinicalTrials.gov ↗ · Immune Thrombocytopenia, Treatment
|
Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | China |
|
A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
NCT07421167 · Primary Immune Thrombocytopenia (ITP), Primary Evans Syndrome (ES)
|
Phase 2 | Recruiting | Novartis Pharmaceuticals | USA |
|
Avatrombopag for Platelet Recovery Post-UCBT in Patients With Bone Marrow Failure Disease
NCT05823376 · ClinicalTrials.gov ↗ · Platelet Recovery After Umbilical Cord Blood Transplantation
|
Observational | Recruiting | Anhui Provincial Hospital | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
1 single-substance product containing Avatrombopag on the HPRA medicines list.
No entry for Avatrombopag in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Novartis Pharmaceuticals | 1 |
| Anhui Provincial Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 3 |
| Clinical trials in USA | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
4 current trials in our China and USA registers name Avatrombopag as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 4 of the 4 trials are recruiting: 3 with sites in China and 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Institute of Hematology & Blood Diseases Hospital, China (2), Novartis Pharmaceuticals (1) and Anhui Provincial Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 1 single-substance product containing Avatrombopag, for example Doptelet 20 mg film-coated tablets (Swedish Orphan Biovitrum AB(publ)). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Avatrombopag has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Avatrombopag works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Avatrombopag works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Avatrombopag (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.